These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 20371696)
1. Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Koyanagi K; O'Day SJ; Boasberg P; Atkins MB; Wang HJ; Gonzalez R; Lewis K; Thompson JA; Anderson CM; Lutzky J; Amatruda TT; Hersh E; Richards J; Weber JS; Hoon DS Clin Cancer Res; 2010 Apr; 16(8):2402-8. PubMed ID: 20371696 [TBL] [Abstract][Full Text] [Related]
2. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. Koyanagi K; O'Day SJ; Gonzalez R; Lewis K; Robinson WA; Amatruda TT; Wang HJ; Elashoff RM; Takeuchi H; Umetani N; Hoon DS J Clin Oncol; 2005 Nov; 23(31):8057-64. PubMed ID: 16258104 [TBL] [Abstract][Full Text] [Related]
3. Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial. Hoshimoto S; Shingai T; Morton DL; Kuo C; Faries MB; Chong K; Elashoff D; Wang HJ; Elashoff RM; Hoon DS J Clin Oncol; 2012 Nov; 30(31):3819-26. PubMed ID: 23008288 [TBL] [Abstract][Full Text] [Related]
4. Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma. Hoshimoto S; Faries MB; Morton DL; Shingai T; Kuo C; Wang HJ; Elashoff R; Mozzillo N; Kelley MC; Thompson JF; Lee JE; Hoon DS Ann Surg; 2012 Feb; 255(2):357-62. PubMed ID: 22202581 [TBL] [Abstract][Full Text] [Related]
6. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma. O'Day SJ; Atkins MB; Boasberg P; Wang HJ; Thompson JA; Anderson CM; Gonzalez R; Lutzky J; Amatruda T; Hersh EM; Weber JS J Clin Oncol; 2009 Dec; 27(36):6207-12. PubMed ID: 19917850 [TBL] [Abstract][Full Text] [Related]
7. Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Koyanagi K; O'Day SJ; Gonzalez R; Lewis K; Robinson WA; Amatruda TT; Kuo C; Wang HJ; Milford R; Morton DL; Hoon DS Clin Cancer Res; 2006 Feb; 12(4):1137-43. PubMed ID: 16489066 [TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of the sequential detection of circulating melanoma cells by RT-PCR in high-risk melanoma patients receiving adjuvant interferon. Gogas H; Kefala G; Bafaloukos D; Frangia K; Polyzos A; Pectasides D; Tsoutsos D; Panagiotou P; Ioannovich J; Loukopoulos D Br J Cancer; 2002 Jul; 87(2):181-6. PubMed ID: 12107840 [TBL] [Abstract][Full Text] [Related]
9. Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. Koyanagi K; Kuo C; Nakagawa T; Mori T; Ueno H; Lorico AR; Wang HJ; Hseuh E; O'Day SJ; Hoon DS Clin Chem; 2005 Jun; 51(6):981-8. PubMed ID: 15817820 [TBL] [Abstract][Full Text] [Related]
10. Quantitative RT-PCR assessment of melanoma cells in peripheral blood during immunotherapy for metastatic melanoma. Schmidt H; Sørensen BS; von der Maase H; Bang C; Agger R; Hokland M; Nexo E Melanoma Res; 2002 Dec; 12(6):585-92. PubMed ID: 12459648 [TBL] [Abstract][Full Text] [Related]
11. Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Koyanagi K; Mori T; O'Day SJ; Martinez SR; Wang HJ; Hoon DS Cancer Res; 2006 Jun; 66(12):6111-7. PubMed ID: 16778184 [TBL] [Abstract][Full Text] [Related]
12. High Number of Circulating Tumor Cells Predicts Poor Survival of Cutaneous Melanoma Patients in China. Li J; Fu W; Zhang W; Li P Med Sci Monit; 2018 Jan; 24():324-331. PubMed ID: 29337932 [TBL] [Abstract][Full Text] [Related]
13. Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma. Klinac D; Gray ES; Freeman JB; Reid A; Bowyer S; Millward M; Ziman M BMC Cancer; 2014 Jun; 14():423. PubMed ID: 24915896 [TBL] [Abstract][Full Text] [Related]
14. Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Shinozaki M; O'Day SJ; Kitago M; Amersi F; Kuo C; Kim J; Wang HJ; Hoon DS Clin Cancer Res; 2007 Apr; 13(7):2068-74. PubMed ID: 17404088 [TBL] [Abstract][Full Text] [Related]
15. Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study). Fusi A; Collette S; Busse A; Suciu S; Rietz A; Santinami M; Kruit WH; Testori A; Punt CJ; Dalgleish AG; Spatz A; Eggermont AM; Keilholz U Eur J Cancer; 2009 Dec; 45(18):3189-97. PubMed ID: 19793643 [TBL] [Abstract][Full Text] [Related]
16. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Legha SS; Ring S; Bedikian A; Plager C; Eton O; Buzaid AC; Papadopoulos N Ann Oncol; 1996 Oct; 7(8):827-35. PubMed ID: 8922197 [TBL] [Abstract][Full Text] [Related]
18. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. O'Day SJ; Boasberg PD; Piro L; Kristedja TS; Wang HJ; Martin M; Deck R; Ames P; Shinn K; Kim H; Fournier P; Gammon G Clin Cancer Res; 2002 Sep; 8(9):2775-81. PubMed ID: 12231516 [TBL] [Abstract][Full Text] [Related]
19. Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression. Reid AL; Millward M; Pearce R; Lee M; Frank MH; Ireland A; Monshizadeh L; Rai T; Heenan P; Medic S; Kumarasinghe P; Ziman M Br J Dermatol; 2013 Jan; 168(1):85-92. PubMed ID: 23013138 [TBL] [Abstract][Full Text] [Related]
20. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. Atkins MB; Hsu J; Lee S; Cohen GI; Flaherty LE; Sosman JA; Sondak VK; Kirkwood JM; J Clin Oncol; 2008 Dec; 26(35):5748-54. PubMed ID: 19001327 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]